首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time
【24h】

Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time

机译:控制的聚山梨醇酯20水解 - 一种评估聚山梨醇酯20对缩短时间缩短生物制药产品质量的影响的新方法

获取原文
获取原文并翻译 | 示例
       

摘要

Hydrolysis of polysorbate in biopharmaceutical liquid formulations upon long-term storage represents a risk factor, since reduction of the intact surfactant concentration may compromise protein stability. Moreover, accumulation of polysorbate degradation products is associated with the formation of particulates potentially affecting drug product stability and quality. These effects are conventionally assessed by real-time end-of-shelf life studies constituting an integral yet lengthy process of formulation development. To accelerate this procedure, we describe here a powerful tool to conduct shake stress studies based on the controlled hydrolysis of polysorbate 20 by beads-immobilized lipases. For this purpose, the production of stable, partially degraded material characterized by a representative presence of non-emulsifying degradants such as ethoxylated sorbitan and free fatty acids was monitored by state-of-the-art chromatographic methods ensuring realistic pharmaceutical conditions. Freeze-thaw, shaking and shipping stress studies of a mAb formulation did not only demonstrate that this approach is useful to determine the critical degradation level impairing drug product quality, but furthermore revealed significant differences in protective effects depending on the hydrolysis pattern. As these results emphasize, the outlined strategy may support formulation scientists to unveil the interrelationship between polysorbate hydrolysis products and stabilization of the active pharmaceutical ingredient in a holistic and time-saving manner.
机译:在长期储存后的生物制药液体制剂中的多元浆酸盐的水解代表危险因素,因为未降低完整的表面活性剂浓度可能会损害蛋白质稳定性。此外,聚山梨醇酯降解产物的积累与潜在地影响药品稳定性和质量的颗粒的形成有关。这些效果通常是通过实时保质期终生物研究来评估,构成了整体但漫长的配方发展过程。为了加速这一程序,我们在这里描述了一种强大的工具,可以通过珠粒固定化脂肪酶对多晶硅化物20的受控水解进行摇动应力研究。为此目的,通过最先进的色谱法监测通过最先进的色谱法监测稳定的,部分降解材料,其特征在于乙氧基化降解剂如乙氧基化降解剂等的代表性存​​在,确保现实的药物条件。 MAB制剂的冻融,摇晃和运输应力研究不仅证明这种方法可用于确定危重的降解水平损害药物产品质量,但此外,根据水解模式揭示了保护作用的显着差异。随着这些结果强调,所述概述的策略可以支持配方科学家揭示聚山梨醇酯水解产物与活性药物成分的稳定化以整体和节省时间的稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号